{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T15:30:08Z","timestamp":1768750208860,"version":"3.49.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2012,9,1]],"date-time":"2012-09-01T00:00:00Z","timestamp":1346457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2012,9]]},"DOI":"10.1016\/j.clinthera.2012.07.007","type":"journal-article","created":{"date-parts":[[2012,8,9]],"date-time":"2012-08-09T19:46:58Z","timestamp":1344541618000},"page":"1892-1908.e1","source":"Crossref","is-referenced-by-count":70,"title":["Efficacy and Safety Profile of Exenatide Once Weekly Compared With Insulin Once Daily in Japanese Patients With Type 2 Diabetes Treated With Oral Antidiabetes Drug(s): Results From a 26-Week, Randomized, Open-Label, Parallel-Group, Multicenter, Noninferiority Study"],"prefix":"10.1016","volume":"34","clinical-trial-number":[{"clinical-trial-number":"nct00935532","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Nobuya","family":"Inagaki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihito","family":"Atsumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomonori","family":"Oura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitoshi","family":"Saito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Imaoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2012.07.007_bib1","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1111\/j.1463-1326.2011.01357.x","article-title":"An overview of once-weekly GLP-1 receptor agonists\u2014available efficacy and safety data and perspectives for the future","volume":"13","author":"Madsbad","year":"2011","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.clinthera.2012.07.007_bib2","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.diabres.2010.07.006","article-title":"DPP-4 inhibitors: what may be the clinical differentiators?","volume":"90","author":"Gerich","year":"2010","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.clinthera.2012.07.007_bib3","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.2165\/11205080-000000000-00000","article-title":"Alogliptin: a review of its use in the management of type 2 diabetes mellitus","volume":"70","author":"Scott","year":"2010","journal-title":"Drugs"},{"key":"10.1016\/j.clinthera.2012.07.007_bib4","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.clinthera.2011.04.024","article-title":"Clinical pharmacology of incretin therapies for type 2 diabetes mellitus: implications for treatment","volume":"33","author":"Neumiller","year":"2011","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2012.07.007_bib5","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1053\/meta.2001.22519","article-title":"Insulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitro","volume":"50","author":"Parkes","year":"2001","journal-title":"Metabolism"},{"key":"10.1016\/j.clinthera.2012.07.007_bib6","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1210\/jc.87.3.1282","article-title":"The insulinotropic effect of acute exendin-4 administered to humans: comparison of nondiabetic state to type 2 diabetes","volume":"87","author":"Egan","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.clinthera.2012.07.007_bib7","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.2337\/diabetes.53.9.2397","article-title":"Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucose-dependent insulin secretion and counterregulation during hypoglycemia","volume":"53","author":"Degn","year":"2004","journal-title":"Diabetes"},{"key":"10.1016\/j.clinthera.2012.07.007_bib8","doi-asserted-by":"crossref","first-page":"3082","DOI":"10.1210\/jc.2002-021545","article-title":"Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes","volume":"88","author":"Kolterman","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.clinthera.2012.07.007_bib9","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1093\/ajhp\/62.2.173","article-title":"Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus","volume":"62","author":"Kolterman","year":"2005","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.clinthera.2012.07.007_bib10","doi-asserted-by":"crossref","first-page":"E155","DOI":"10.1152\/ajpendo.2001.281.1.E155","article-title":"Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers","volume":"281","author":"Edwards","year":"2001","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.clinthera.2012.07.007_bib11","doi-asserted-by":"crossref","first-page":"559","DOI":"10.7326\/0003-4819-143-8-200510180-00006","article-title":"Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial","volume":"143","author":"Heine","year":"2005","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clinthera.2012.07.007_bib12","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1016\/j.clinthera.2007.11.006","article-title":"Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial","volume":"29","author":"Barnett","year":"2007","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2012.07.007_bib13","doi-asserted-by":"crossref","first-page":"762","DOI":"10.2337\/dc08-1797","article-title":"One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial","volume":"32","author":"Bunck","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2012.07.007_bib14","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1111\/j.1463-1326.2009.01154.x","article-title":"Exenatide compared with long-acting insulin to achieve glycaemic control with minimal weight gain in patients with type 2 diabetes: results of the Helping Evaluate Exenatide in patients with diabetes compared with Long-Acting insulin (HEELA) study","volume":"11","author":"Davies","year":"2009","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.clinthera.2012.07.007_bib15","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.2040-1124.2010.00084.x","article-title":"Improved glycemic control and reduced bodyweight with exenatide: a double-blind, randomized, Phase 3 study in Japanese patients with suboptimally controlled type 2 diabetes over 24 weeks","volume":"2","author":"Kadowaki","year":"2011","journal-title":"J Diabetes Invest"},{"key":"10.1016\/j.clinthera.2012.07.007_bib16","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1111\/j.2040-1124.2011.00137.x","article-title":"Long-term safety and efficacy of exenatide twice daily in Japanese patients with suboptimally controlled type 2 diabetes","volume":"2","author":"Inagaki","year":"2011","journal-title":"J Diabetes Invest"},{"key":"10.1016\/j.clinthera.2012.07.007_bib17","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/S0140-6736(08)61206-4","article-title":"Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study","volume":"372","author":"Drucker","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2012.07.007_bib18","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1210\/jc.2010-2081","article-title":"DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes","volume":"96","author":"Blevins","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.clinthera.2012.07.007_bib19","series-title":"Treatment Guide for Diabetes","year":"2012"},{"key":"10.1016\/j.clinthera.2012.07.007_bib20","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.2337\/diacare.28.11.2673","article-title":"Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study","volume":"28","author":"Peyrot","year":"2005","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2012.07.007_bib21","doi-asserted-by":"crossref","first-page":"136","DOI":"10.2337\/diaspect.18.3.136","article-title":"The Diabetes Attitudes, Wishes, and Needs (DAWN) Program: a new approach to improving outcomes of diabetes care","volume":"18","author":"Skovlund","year":"2005","journal-title":"Diabetes Spectrum"},{"key":"10.1016\/j.clinthera.2012.07.007_bib22","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1900\/RDS.2005.2.35","article-title":"Type 2 diabetes\u2014failure, blame and guilt in the adoption of insulin therapy","volume":"2","author":"Phillips","year":"2005","journal-title":"Rev Diabet Stud"},{"key":"10.1016\/j.clinthera.2012.07.007_bib23","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.2337\/dc06-2375","article-title":"Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes","volume":"30","author":"Kim","year":"2007","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2012.07.007_bib24","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1016\/S0140-6736(10)60406-0","article-title":"Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial","volume":"375","author":"Diamant","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2012.07.007_bib25","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1507\/endocrj.K09E-147","article-title":"Safety, tolerability, pharmacokinetics, and pharmacodynamics of exenatide once weekly in Japanese patients with type 2 diabetes","volume":"56","author":"Iwamoto","year":"2009","journal-title":"Endocr J"},{"key":"10.1016\/j.clinthera.2012.07.007_bib26","doi-asserted-by":"crossref","first-page":"950","DOI":"10.2337\/diacare.28.4.950","article-title":"Reduced hypoglycemia risk with insulin glargine: a meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes","volume":"28","author":"Rosenstock","year":"2005","journal-title":"Diabetes Care"},{"issue":"Suppl 2","key":"10.1016\/j.clinthera.2012.07.007_bib27","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/j.1463-1326.2008.00842.x","article-title":"Insulin glargine in type 2 diabetes in everyday clinical practice: 7 years experience","volume":"10","author":"Schreiber","year":"2008","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.clinthera.2012.07.007_bib30","series-title":"Definition, diagnosis and classification of diabetes mellitus and its complications","year":"1999"},{"key":"10.1016\/j.clinthera.2012.07.007_bib31","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.2337\/diacare.26.8.2370","article-title":"Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and\/or sulfonylurea treatment in patients with type 2 diabetes","volume":"26","author":"Fineman","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2012.07.007_bib32","series-title":"Statistical Methods in Medical Research","author":"Armitage","year":"2002"},{"key":"10.1016\/j.clinthera.2012.07.007_bib33","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1111\/j.1463-1326.2012.01561.x","article-title":"Clinical relevance of anti-exenatide antibodies: safety, efficacy and cross-reactivity with long-term treatment","volume":"14","author":"Fineman","year":"2012","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.clinthera.2012.07.007_bib34","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.2337\/diacare.27.11.2628","article-title":"Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes","volume":"27","author":"Buse","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2012.07.007_bib35","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.2337\/diacare.28.5.1092","article-title":"Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes","volume":"28","author":"DeFronzo","year":"2005","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2012.07.007_bib36","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.2337\/diacare.28.5.1083","article-title":"Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea","volume":"28","author":"Kendall","year":"2005","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2012.07.007_bib37","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s00125-006-0510-2","article-title":"A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study","volume":"50","author":"Nauck","year":"2007","journal-title":"Diabetologia"},{"key":"10.1016\/j.clinthera.2012.07.007_bib38","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1507\/endocrj.K08E-296","article-title":"Exenatide exhibits dose-dependent effects on glycemic control over 12 weeks in Japanese patients with suboptimally controlled type 2 diabetes","volume":"56","author":"Kadowaki","year":"2009","journal-title":"Endocr J"},{"key":"10.1016\/j.clinthera.2012.07.007_bib39","doi-asserted-by":"crossref","first-page":"477","DOI":"10.7326\/0003-4819-146-7-200704030-00003","article-title":"The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial","volume":"146","author":"Zinman","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clinthera.2012.07.007_bib40","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1002\/dmrr.499","article-title":"Effectiveness of progressive dose-escalation of exenatide (exendin-4) in reducing dose-limiting side effects in subjects with type 2 diabetes","volume":"20","author":"Fineman","year":"2004","journal-title":"Diabetes Metab Res Rev"},{"key":"10.1016\/j.clinthera.2012.07.007_bib41","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1517\/13543784.17.6.845","article-title":"Incretin mimetics and dipeptidyl peptidase 4 inhibitors in clinical trials for the treatment of type 2 diabetes","volume":"17","author":"Mikhail","year":"2008","journal-title":"Expert Opin Investig Drugs"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291812004341?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291812004341?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,2]],"date-time":"2019-07-02T18:00:21Z","timestamp":1562090421000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291812004341"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9]]},"references-count":39,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2012,9]]}},"alternative-id":["S0149291812004341"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2012.07.007","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2012,9]]}}}